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Objectives: In 2003, a skin cancer screening
campaign based on total body skin examination was
launched in the federal state of Schleswig-Holstein,
Germany. 20% of adults aged 20 and over were
screened. In 2008, a 48% decline in melanoma
mortality was reported. In the same year, skin
screening was extended to the rest of Germany.
We evaluated whether melanoma mortality trends
decreased in Germany as compared with surrounding
countries where skin screening is uncommon. We also
evaluated whether the initial decreasing mortality trend
observed in Schleswig-Holstein was maintained with a
longer follow-up.
Setting and participants: Regional and national
melanoma mortality data from 1995 to 2013 were
extracted from the GEKID database and the Federal
Statistical Office. Mortality data for Germany and
surrounding countries from 1980 to 2012 were
extracted from the WHO mortality database.
Primary and secondary outcome measures:
Age-adjusted (European Standard Population) mortality
rates were computed and joinpoint analysis performed
for Schleswig-Holstein, Germany and surrounding
countries.
Results: In Schleswig-Holstein, melanoma mortality
rates declined by 48% from 2003 to 2008, and from
2009 to 2013 returned to levels observed before
screening initiation. During the 5 years of the national
programme (2008–2012), melanoma mortality rates
increased by 2.6% (95% CI −0.1 to 5.2) in men and
0.02% (95% CI −1.8 to 1.8) in women. No inflexion
point in trends was identified after 2008 that could
have suggested a decreasing melanoma mortality.
Trends of cutaneous melanoma mortality in Germany
from 1980 to 2012 did not differ from those observed
in surrounding countries.
Conclusions: The transient decrease mortality in
Schleswig-Holstein followed by return to pre-screening
levels could reflect a temporal modification in the
reporting of death causes. An in-depth evaluation of
the screening programme is required.
INTRODUCTION
Many public health agencies like the United
States Preventive Services Task Force
(USPSTF) or the National Institute for Health
and Care Excellence (NICE) in the UK do not
recommend skin cancer screening. This prac-
tice, however, tends to increase: 14.5% of
adults in the USA in 2000 had at least one
total body skin examination (TBSE), this
ﬁgure increased to 19.8% in 2010.1
In 2003, a skin cancer screening campaign
(the SCREEN (Skin Cancer Research to
Provide Evidence for Effectiveness of
Screening in Northern Germany) project)
was initiated in the federal state of Schleswig–
Holstein in Germany.2 This campaign was
based on TBSE offered from July 2003 to
June 2004 to individuals aged 20 and over by
dermatologists and by non-dermatologist
practitioners who had followed an 8 h train-
ing course. These TBSE were fully covered by
health insurances; physicians received a ﬁnan-
cial incentive of €15 per screening. No invita-
tion or follow-up system was implemented,
but the population was informed about the
campaign by a large-scale mass media
Strengths and limitations of this study
▪ The present study replicates, with a follow-up
time doubled, the analysis that was conducted in
the region of Schleswig–Holstein, Germany,
showing a 48% decline in cutaneous melanoma
mortality 5 years after initiation of a skin cancer
screening campaign based on total body skin
examination.
▪ In addition, this study evaluates using a similar
method, with 5 years of follow-up, the impact in
the whole of Germany where a skin cancer
screening programme was introduced since
2008.
▪ A limitation of such an approach, as in the ori-
ginal approach that was used in Schleswig-
Holstein, is the ecological design.
▪ Another limitation is that there is currently a lack
of useful process and outcome evaluation of the
skin cancer screening. This represents a major
failure of the German screening programme.
▪ However, the current unique situation in
Germany represents a quasi-experimental setting
in Europe to evaluate whether such a massive
introduction of total body skin examination in the
general population is effective in decreasing mel-
anoma mortality.
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campaign. The participation rate was 19% (27% in
women and 10% in men) to 21.5%.3 4 In 2008, melan-
oma mortality rates were reported to have dropped by
47% and 49% in Schleswig–Holstein men and women,
respectively.5
Many considered that the 5-year results of the SCREEN
project represented compelling evidence that skin cancer
screening based on TBSE could be effective.5 6 In 2008, a
national programme was implemented in Germany,
including Schleswig–Holstein, following screening proce-
dures adopted in the SCREEN project but starting at age
35.7 Simulation studies foresaw that biennial TBSE of the
German population aged 35–85 years and a 20% participa-
tion would reduce melanoma mortality by 45% 20 years
after screening implementation.8 Screening in the
national programme experienced divergences from the
initial programme as some insurance companies agreed to
reimburse additional services proposed by practitioners.
Screening could be performed in adults less than 35 years
of age with a shorter interval between screening rounds,
and assessment of pigmented lesions could be carried out
using computer or video technologies.9
In this study, we evaluated whether the reported
decreases in melanoma mortality in Schleswig–Holstein
were maintained over time. Then we analysed changes
in melanoma mortality in Germany in the 5 years follow-
ing implementation of the national programme using
statistical methods similar to those used for the evalu-
ation of the SCREEN project in Schleswig–Holstein. We
also computed melanoma mortality trends in Germany
for different age groups and compared them with trends
in surrounding countries where a similar skin cancer
screening programme does not exist.
MATERIAL AND METHODS
Incidence and regional mortality data in Germany were
extracted from the GEKID database.10 Melanoma inci-
dence data were available for the period 2003–2011.
Melanoma mortality was extracted for the whole of
Germany as well as for Schleswig–Holstein from the
GEKID database for the period 1995–2012 and from the
Federal Statistical Ofﬁce for the period 1998–2013.11 The
latter data source was used for completing the GEKID
database for the year 2013. Both data sources, GEKID and
Federal Statistical Ofﬁce, reported identical ﬁgures for
years they had in common, ie 1998–2012. For the compari-
son of melanoma mortality rates, melanoma mortality data
of Germany and of surrounding countries (the Czech
Republic, Denmark, Austria, Belgium, France, Poland, the
Netherlands and Switzerland) were extracted from the
WHO mortality database (update of November 2014).
International classiﬁcation of disease (ICD) codes of
extracted data were ICD 8 172, ICD 9 172 and ICD 10 C43.
Age-standardised (European Standard Population)
incidence and mortality rates were computed. For
Germany and surrounding countries, annual per cent
changes (APC) in mortality were then computed for the
period 1980–2012, and for the period 2008–2012, that is
for the 5 years following the introduction of screening in
Germany.
Temporal trends of melanoma mortality were analysed
from 1980 to 2012 in Germany and surrounding coun-
tries using joinpoint regression.12 Joinpoint software ﬁts
a series of straight lines connected on a common point,
called ‘joinpoint’, on a logarithmic scale to the annual
age-standardised rates. The selected number of lines
and points of inﬂexion, if any, is based on the simplest
model that the data allow.13 The programme uses per-
mutation analysis with a grid search algorithm to identify
inﬂexions in trends with an overall statistical signiﬁcance
level of 0.05. We kept default settings in the programme,
that is, allowing up to ﬁve possible joinpoints during
1980–2012, with three observations from a joinpoint to
either end of the data and four observations between
two joinpoints. We reported trends for the last uninter-
rupted segment identiﬁed in the joinpoint regression by
age groups: less than 60, 60–74, and 75 and over.
RESULTS
Melanoma mortality in Schleswig–Holstein
Melanoma mortality dropped in the years immediately
following the pilot project that took place in 2001
(ﬁgure 1). In 2008, melanoma mortality rates were well
below the rates reported for Germany. In 2009–2010, a
doubling of mortality rates took place, and in 2012 and
2013, the melanoma rates were close to the rates
observed before the pilot project.
Melanoma incidence and mortality in Germany
Schleswig–Holstein has a population size of 2 806 000
people, it represents 3.5% of all Germany. In Schleswig–
Holstein before the SCREEN project started (1998–
1999), the age-standardised melanoma mortality rate
(World Standard Population) was 1.9 per 100 000 for
men and 1.4 per 100 000 for women. Melanoma mortal-
ity declined by 47% to 1.0 per 100 000 men and by 49%
to 0.7 per 100 000 women by 2008/2009. The APC in
the period 2000–2009 was −7.5% (95% CI −14.0 to
−0.5) for men and −7.1% (95% CI −10.5 to −2.9) for
women. In each of the four adjacent regions and in the
rest of Germany, the mortality rates were stable.5
Overall, in Germany, the average participation rate in
the skin cancer screening programme from January
2009 to December 2010 reached 30.8%.14 The launch of
the national screening programme was immediately fol-
lowed by a 29% rise in the incidence of cutaneous mel-
anoma in both sexes (ﬁgure 2), from about 14.5 cases
per 100 000 person-years in 2006 to 18.0 cases per
100 000 person-years in 2010.
From 1980 to 2012, the melanoma mortality rate in
Germany remained ﬂat with an APC of 0.44% in men
and of −0.15% in women (table 1).
In the 5-year period following the introduction of the
national screening programme, melanoma mortality
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rates increased by 2.60% in men and 0.02% in women.
Hence, upward trends were more marked in the years
after screening introduction than during the whole
period. The joinpoint analysis did not identify a change
in trends after 2008 that could have suggested some
downward inﬂexion in mortality. The last inﬂexion in
men was observed in 1996 followed by a monotonic sig-
niﬁcant increase in mortality of 0.8% (95% CI 0.4 to 1.3;
ﬁgure 3). In women, the last downward inﬂexion was
observed in 1997, also followed by a monotonic signiﬁ-
cant increase of 0.4% (95% CI 0.0 to 0.8).
Comparison with surrounding countries
For men and women, trends in melanoma mortality in
Germany did not differ from trends in surrounding
countries (ﬁgure 3). No decline in melanoma mortality
was observed in the surrounding countries, except in
Austrian women in whom a decline of −0.9% per year
(95% CI −1.8% to −0.0%) took place after 1994.
Analysis of trends by age group (table 2) did not indi-
cate any particular difference in most recent trends in
Germany and in surrounding countries.
DISCUSSION
The decline in melanoma mortality reported in the
5 years immediately following the start of the SCREEN
project in Schleswig–Holstein was transient and during
the next 5 years, rates returned to levels prevailing prior
to the introduction of screening. Introduction of
Figure 2 Trend in cutaneous
melanoma incidence in Germany.
Data from GEKID as of
10 December 2014. Vertical
line=introduction of screening at a
national level. Note that for better
display, Y-axis starts at 10 cases
per 100 000 person-years.
Figure 1 Trend in cutaneous
melanoma mortality in the
screened area Schleswig–
Holstein (SH) as compared with
the whole of Germany. Data from
the Federal Statistical Office
(http://www.gbe-bund.de) as of
15 December 2014 and from
GEKID as of 10 December 2014.
Box=period of SCREEN project
(Skin Cancer Research to
Provide Evidence for
Effectiveness of Screening in
Northern Germany) ( July 2003–
June 2004).
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screening in Germany led to signiﬁcant increases in the
number of diagnoses of cutaneous melanoma similar to
increases reported in Schleswig–Holstein after the intro-
duction of the SCREEN project.2 In the German study,
invasive melanoma diagnoses increased by 53% in
women in Schleswig–Holstein with screening, compared
with 18% in another city, Saarland, which had no screen-
ing. A similar effect was observed in men with a 26%
increase in Schleswig–Holstein compared with 10% in
Saarland.15 But contrary to Schleswig–Holstein where
melanoma mortality decreased in the ﬁve years after
introduction of screening, trends in melanoma mortality
in the whole of Germany did not decrease in years fol-
lowing introduction of screening. In addition, mortality
trends in Germany in recent years did not differ from
those in surrounding countries.
There is currently no systematic comprehensive evalu-
ation of the skin cancer screening programme in
Germany. Data needed for a proper understanding of
differences between the SCREEN project and the
national screening programme are lacking. Several
factors suggest that the national programme was more
intense with a higher participation rate than in the
SCREEN project, additional services offered by insur-
ance companies and a continuous programme. In con-
trast, the screening period of the SCREEN project only
lasted 12 months. In view of initial results of the
SCREEN project, some decline in melanoma mortality
for all of Germany should have been observed in the
years immediately following the introduction of the
national skin cancer screening programme. It could be
argued that more years of observation are needed
before an impact on melanoma mortality could show
up. If the latter argument is considered valid, then the
likelihood of the 48% reduction in melanoma mortality
in 2003–2008 reported for Schleswig–Holstein is ques-
tionable: in fact, both mortality reduction and its
association with screening are questionable. In addition,
the return in 2012–2013 to melanoma mortality rates
prevailing before the start of the screening campaign
further questions the likelihood of the transient drop in
mortality reported for Schleswig–Holstein. The issue of
lead time is central to the interpretation of these data. It
has been estimated that it would take at least 5–7 years
for an effective screening programme to potentially
decrease mortality.16 Additional elements raise scepti-
cism about the likelihood of the SCREEN project
results.7 17 For instance, a low 20% participation in
screening and a high 48% reduction in melanoma mor-
tality are hardly compatible. The decline in melanoma
mortality actually started 2 years before the launch of
the SCREEN project, which cast doubt on whether skin
screening was the actual cause for mortality reductions.
The analysis of impact of skin cancer screening in
Germany and in particular in Schleswig–Holstein would
beneﬁt from data on trends in melanoma incidence by
stage. Unfortunately, such data are not systematically
reported to cancer registries in Germany. Even in
Schleswig–Holstein, covered by a cancer registry of good
quality, a study between 2000 and 2008 showed that
69.5% of melanoma cases have an unknown Union for
International Cancer Control (UICC) stage.18
In view of these elements, skin cancer screening is most
probably not the cause of the transient reduction in mel-
anoma mortality in Schleswig–Holstein, and the possible
contribution of other factors needs to be evoked. A ﬁrst
possibility could be random variation in trends because
of the relatively small number of melanoma deaths occur-
ring each year in Schleswig–Holstein. For each sex, about
42 melanoma deaths per year were reported in
Schleswig–Holstein,5 which resulted in important ﬂuctua-
tions in the estimation of mortality rate (ﬁgure 1).
Another possibility could be a bias in the ascertainment
of the causes of death. Certiﬁcations of the causes of
Table 1 Melanoma mortality annual per cent change for all ages for men and women between 1980 and 2012 and in the




change (%) (95% CI)
1980–2012
Annual per cent
change (%) (95% CI)
2008–2012
Annual per cent
change (%) (95% CI)
1980–2012
Annual per cent
change (%) (95% CI)
2008–2012
Germany 0.44 (0.26 to 0.62) 2.57 (−0.10 to 5.24) −0.15 (−0.30 to 0.00) 0.02 (−1.79 to 1.82)
Czech Republic* −0.55 (−0.91 to −0.20) 0.65 (−4.57 to 5.88) −0.90 (−1.41 to −0.39) −0.25 (−4.40 to 3.90)
Poland 2.70 (2.43 to 2.97) 1.19 (−0.64 to 3.01) 1.62 (1.28 to 1.97) 1.28 (−0.85 to 3.42)
Denmark† 0.60 (0.17 to 1.03) −1.70 (−7.51 to 4.11) −0.11 (−0.64 to 0.41) −1.70 (−9.61 to 6.21)
Austria 0.84 (0.40 to 1.28) −0.06 (−1.17 to 1.04) 0.29 (−0.11 to 0.69) 2.17 (−7.11 to 11.5)
Belgium‡ 2.10 (1.77 to 2.60) −2.74 (−7.18 to 1.71) 2.22 (1.74 to 2.84) −1.17 (−5.74 to 3.41)
France‡ 2.20 (2.03 to 2.37) 1.96 (−1.60 to 5.51) 1.23 (0.97 to 1.49) 2.64 (−9.63 to 14.9)
The Netherlands 2.54 (2.31 to 2.76) 1.04 (−3.34 to 5.42) 1.79 (1.48 to 2.10) −0.82 (−6.33 to 4.69)
Switzerland‡ 0.33 (−0.06 to 0.72) 4.28 (−3.85 to 12.4) −0.37 (−0.78 to 0.04) −1.21 (−3.11 to 0.69)
In bold, significant trends.
*Data available from 1986.
†Data available until 2011.
‡Data available until 2010.
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death in Germany are performed by physicians having
their practice in the municipality where the postmortem
examination takes place.19 Three-quarters of physicians
established in Schleswig–Holstein with outpatient activ-
ities (including surgeons, gynaecologists, urologists) par-
ticipated in the SCREEN project. The SCREEN project
beneﬁted from intense mass media coverage.4 Within this
context, we hypothesise that doctors practising in
Schleswig–Holstein would have under-reported melan-
oma as the underlying cause of death. Such a bias is very
likely because the SCREEN project was not a randomised
controlled trial with blinding of cause of death assessors
for the screening status of subjects. In addition, doctors
were the entry point of participants in the SCREEN
project; they were entitled to perform TBSE, and they
were motivated by a ﬁnancial incentive for each TBSE.6
The combined effect of these factors could have contrib-
uted to inducing a systematic bias in the causes of death
reported on death certiﬁcates.
Unbiased ascertainment of causes of death is a chal-
lenge in studies having death due to a speciﬁc disease as
the principal outcome. Even randomised trials on
cancer screening are not immune to ascertainment bias.
For instance, in the Swedish trials on breast cancer
screening, cause of death committees or doctors com-
pleting death certiﬁcates knew or could guess which
women had been invited to screening. A still ongoing
controversy is to know whether the absence of true
blinding of cause of death assessors may have intro-
duced bias in the results of these trials.20
Figure 3 Trend in cutaneous
melanoma mortality in Germany
and surrounding countries in (A)
men and (B) women. Data from
the WHO mortality database
(November 2014 release). Each
dot represents the actual
age-standardised rate for each
country and year, and the
corresponding regression lines
were computed by the joinpoint
model.
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CONCLUSION
The analysis of trends of melanoma mortality in
Germany and in Schleswig–Holstein does not provide
evidence that skin cancer screening is effective for pre-
venting melanoma death. We hypothesise that a highly
plausible reason for the transient decline in melanoma
mortality reported in Schleswig–Holstein after screening
start would be that the SCREEN project altered the way
doctors reported the causes of death. If this hypothesis
turned out to be grounded, then the German skin
cancer screening programme would no longer be justi-
ﬁed. The lack of a comprehensive evaluation is a major
failure of the German screening programme.
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